Clinical Trials
233 trialsNCT06820463 2026-05-27
AndroMETa-CRC
AbbVie
Phase 2 Recruiting
NCT02350530 2026-05-22
FORBES
Sun Yat-sen University
Phase 2 Completed
NCT07359456 2026-05-19
COLIBRI-GI
UNICANCER
Phase 2 Not yet recruiting
NCT06948448 2026-05-18
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT06792695 2026-05-11
CANTOR
AstraZeneca
Phase 2 Recruiting
NCT00959647 2026-05-08
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT07503756 2026-05-05
JS212 Combination Therapies in Metastatic Colorectal Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT07562490 2026-05-01
CLEAR-04
Fudan University
Phase 2 Recruiting
NCT07559760 2026-04-30
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
The First Hospital of Jilin University
Phase 2 Recruiting
NCT07535632 2026-04-17
BEST
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT04245865 2026-04-03
Toco-CoR
Vejle Hospital
Phase 2 Active not recruiting
NCT05854498 2026-04-02
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Recruiting
NCT05489211 2026-03-19
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
Phase 2 Recruiting
NCT07071714 2026-03-18
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07474727 2026-03-16
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2 Not yet recruiting
NCT06607458 2026-03-13
DEL-LIVER
Delcath Systems Inc.
Phase 2 Recruiting
NCT05983367 2026-02-20
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
Phase 2 Terminated
NCT07407465 2026-02-17
CHIMERA
Gruppo Oncologico del Nord-Ovest
Phase 2 Recruiting
NCT04109924 2026-02-10
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Phase 2 Completed
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT07395063 2026-02-09
A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT04587128 2026-02-05
Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT06268015 2026-02-05
BBOpCo
Duke University
Phase 2 Active not recruiting
NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune, Inc.
Phase 2 Terminated
NCT07381764 2026-02-02
ROMANCE - GOIM
Gruppo Oncologico Italia Meridionale
Phase 2 Not yet recruiting
NCT07337551 2026-01-13
Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
The Second Hospital of Hebei Medical University
Phase 2 Not yet recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT07229846 2026-01-08
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
Harbin Medical University
Phase 2 Not yet recruiting
NCT06856837 2025-12-12
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
NCT06245356 2025-12-10
TRIFLUOX-DP
UNICANCER
Phase 2 Recruiting
NCT05843188 2025-12-09
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT07261709 2025-12-03
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07253896 2025-11-28
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT06784947 2025-10-02
Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
NCT02982694 2025-10-01
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Vall d'Hebron Institute of Oncology
Phase 2 Terminated
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT03929666 2025-09-12
A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Jazz Pharmaceuticals
Phase 2 Completed
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT07150403 2025-09-08
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
Federation Francophone de Cancerologie Digestive
Phase 2 Not yet recruiting
NCT07134101 2025-08-29
SMARTi-RC01
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06887218 2025-08-27
5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 2 Recruiting
NCT07123441 2025-08-14
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
NCT07106034 2025-08-12
ONTOP
Shanghai Pudong Hospital
Phase 2 Not yet recruiting
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT07071844 2025-07-17
BETWEEN
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Not yet recruiting
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT07021950 2025-06-15
AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07007728 2025-06-06
Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07009145 2025-06-06
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC
Qianfoshan Hospital
Phase 2 Not yet recruiting